Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GB-AOS-2
- Development stage
- Unknown
- Lead developer
- GlycosBio
- Modality
- Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
GB-AOS-2 is a clinical-stage topical therapeutic candidate developed by GlycosBio for the treatment of atopic dermatitis. It is based on the company's proprietary Activated Oil System (AOS), which utilizes engineered lipid technologies to improve the delivery and performance of bioactive molecules. GB-AOS-2 is designed to manage the skin microbiome by selectively targeting pathogens such as *Staphylococcus aureus* while preserving commensal bacteria, thereby restoring microbial diversity and strengthening the skin barrier. In clinical assessments, the formulation has been evaluated for its ability to improve clinical scores (such as the Atopic Dermatitis Severity Index) and reduce lesion-associated dysbiosis by repairing the underlying lipid organization of the skin.
Beyond the preview
Go deeper on GB-AOS-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GB-AOS-2.